Tylah Tully chats with LTR Pharma (ASX:LTP) executive chairman Lee Rodne about its successful pre-Investigational New Drug Application meeting with the US FDA, a major milestone in the development of its SPONTAN product.

It’s also gearing up to launch a new product Roxus, another nasal spray which could help gain access to the US healthcare market, valued over $6 billion dollars.  

This video was developed in collaboration with LTR Pharma, a Stockhead advertiser at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.